News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,227 Results
Type
Article (14491)
Company Profile (105)
Press Release (266631)
Section
Business (92183)
Career Advice (542)
Deals (16193)
Drug Delivery (67)
Drug Development (38921)
Employer Resources (52)
FDA (6696)
Job Trends (6670)
News (157519)
Policy (14455)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Elite (1)
2026 Pharm Country Standard (1)
Academia (479)
Adcomms (6)
Allergies (36)
Alliances (23774)
ALS (39)
Alzheimer's disease (447)
Antibody-drug conjugate (ADC) (40)
Approvals (6738)
Artificial intelligence (109)
Autoimmune disease (7)
Automation (5)
Bankruptcy (156)
Best Places to Work (4851)
BIOSECURE Act (9)
Biosimilars (56)
Biotechnology (43)
Bladder cancer (32)
Brain cancer (17)
Breast cancer (110)
Cancer (795)
Cardiovascular disease (81)
Career advice (466)
Career pathing (11)
CAR-T (36)
Cell therapy (113)
Cervical cancer (7)
Clinical research (32954)
Collaboration (376)
Compensation (227)
Complete response letters (16)
COVID-19 (797)
CRISPR (20)
C-suite (115)
Cystic fibrosis (40)
Data (836)
Denatured (15)
Depression (13)
Diabetes (103)
Diagnostics (1570)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (54)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (44)
Earnings (35412)
Editorial (11)
Employer branding (5)
Employer resources (45)
Events (40503)
Executive appointments (370)
FDA (7182)
Featured Employer (21)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (241)
Gene editing (44)
Generative AI (8)
Gene therapy (114)
GLP-1 (346)
Government (1331)
Grass and pollen (2)
Guidances (25)
Healthcare (4143)
Huntington's disease (6)
IgA nephropathy (9)
Immunology and inflammation (38)
Indications (13)
Infectious disease (837)
Inflammatory bowel disease (59)
Inflation Reduction Act (6)
Influenza (16)
Intellectual property (43)
Interviews (73)
IPO (6401)
IRA (29)
Job creations (2140)
Job search strategy (424)
Kidney cancer (7)
Labor market (17)
Layoffs (191)
Leadership (3)
Legal (3485)
Liver cancer (23)
Lung cancer (112)
Lymphoma (67)
Machine learning (1)
Management (17)
Manufacturing (146)
MASH (32)
Medical device (1910)
Medtech (1912)
Mergers & acquisitions (10032)
Metabolic disorders (279)
Multiple sclerosis (31)
NASH (14)
Neurodegenerative disease (22)
Neuropsychiatric disorders (7)
Neuroscience (648)
NextGen: Class of 2025 (1791)
Non-profit (667)
Northern California (990)
Now hiring (10)
Obesity (149)
Opinion (122)
Ovarian cancer (31)
Pain (54)
Pancreatic cancer (30)
Parkinson's disease (50)
Partnered (6)
Patents (103)
Patient recruitment (33)
Peanut (14)
People (29255)
Pharmaceutical (66)
Pharmacy benefit managers (11)
Phase I (8833)
Phase II (14029)
Phase III (12392)
Pipeline (477)
Podcasts (45)
Policy (57)
Postmarket research (1430)
Preclinical (3441)
Press Release (25)
Prostate cancer (55)
Psychedelics (10)
Radiopharmaceuticals (133)
Rare diseases (182)
Real estate (2697)
Recruiting (18)
Regulatory (10500)
Reports (21)
Research institute (597)
Resumes & cover letters (72)
Rett syndrome (1)
RNA editing (1)
RSV (8)
Schizophrenia (40)
Series A (40)
Series B (16)
Service/supplier (4)
Sickle cell disease (36)
Southern California (971)
Special edition (10)
Spinal muscular atrophy (77)
Sponsored (8)
Startups (1669)
State (2)
Stomach cancer (3)
Supply chain (31)
The Weekly (28)
United States (8914)
Vaccines (173)
Venture capitalists (14)
Webinars (10)
Weight loss (95)
Women's health (9)
Worklife (3)
Date
Today (54)
Last 7 days (260)
Last 30 days (1362)
Last 365 days (15658)
2025 (3589)
2024 (15797)
2023 (15839)
2022 (21100)
2021 (21624)
2020 (20269)
2019 (15926)
2018 (12430)
2017 (14780)
2016 (13709)
2015 (15980)
2014 (12795)
2013 (10820)
2012 (11667)
2011 (12220)
2010 (11142)
Location
Africa (346)
Alabama (16)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (21073)
Australia (2724)
California (2319)
Canada (991)
China (237)
Colorado (112)
Connecticut (133)
Delaware (85)
Europe (41370)
Florida (385)
Georgia (56)
Idaho (9)
Illinois (243)
India (14)
Indiana (146)
Iowa (3)
Japan (91)
Kansas (54)
Kentucky (12)
Maine (3)
Maryland (302)
Massachusetts (1855)
Michigan (50)
Minnesota (105)
Missouri (27)
Montana (8)
Nebraska (8)
Nevada (14)
New Hampshire (8)
New Jersey (829)
New Mexico (7)
New York (609)
North Carolina (404)
North Dakota (2)
Northern California (990)
Ohio (66)
Oklahoma (4)
Oregon (17)
Pennsylvania (527)
Puerto Rico (8)
Rhode Island (9)
South America (547)
South Carolina (2)
Southern California (971)
Tennessee (39)
Texas (304)
Utah (43)
Virginia (77)
Washington D.C. (31)
Washington State (168)
Wisconsin (32)
281,227 Results for "x4 pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient population with chronic neutropenia.
February 6, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 25, 2025
·
18 min read
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2025
February 4, 2025
·
1 min read
Deals
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3, 2024
X4 Pharmaceuticals today announced that, effective on May 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc.
June 3, 2024
·
1 min read
Press Releases
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
February 6, 2025
·
6 min read
Press Releases
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
March 12, 2025
·
1 min read
Press Releases
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
January 24, 2025
·
10 min read
Press Releases
Bruker Launches X4 POSEIDON™ Advanced X-Ray Microscope for Three-Dimensional Microscopy in Industrial and Scientific Applications
February 28, 2025
·
2 min read
Press Releases
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
November 14, 2024
·
1 min read
Press Releases
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
February 19, 2025
·
10 min read
1 of 28,123
Next
